 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
Overview | Abacavir (Ziagen) | Abacavir/Lamivudine (Epzicom, Kivexa) | Didanosine (ddI, Videx) | Emtricitabine (FTC, Emtriva) | Lamivudine (3TC, Epivir) | Stavudine (d4T, Zerit) | Tenofovir (Viread) | Tenofovir/Emtricitabine (Truvada) | Zalcitabine (ddC, Hivid) | Zidovudine (AZT, Retrovir) | Zidovudine/Lamivudine (Combivir) | Zidovudine/Lamivudine/Abacavir (Trizivir)
Overview
- Characteristics of Nucleoside Reverse Transcriptase Inhibitors (PDF) (January 29, 2008)
An excerpt from the official U.S. HIV treatment guidelines for adults and adolescents. For the full guidelines, click here (PDF).
From AIDSinfo - Adverse Effects of Antiretroviral Drugs: NRTIs (November 2007)
A table summarizing the most common and most serious adverse events associated with NRTIs.
From HIV InSite Knowledge Base Chapter - Summary of NRTI Dosing and Administration Recommendations (November 2001)
In HEPP News, from Brown Medical School - Long-Term Virologic and Immune Responses in Subjects Maintained on Exclusive Nucleoside Analog (NRTI)-Based Therapy in ACTG 364 (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Use of Trizivir to Simplify Therapy in HAART-Experienced Patients With Long-Term Suppression of HIV-RNA: TRIZAL Study (AZL30002) -- 24-Week Results (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  |
  |